OREANDA-NEWS. May 05, 2014. “Baxter” CJSC withdrew an appeal lodged to the 9th Arbitration Appeal Court to invalidate a FAS warning that refusing to supply a unique drug for treating renal deficiency through peritoneal dialysis was unacceptable. The Appeal Court accepted the withdrawal and terminated the proceedings on the case on “Baxter” CJSC violating the antimonopoly law.

On 27th January 2014, Moscow Arbitration Court confirmed legitimacy of the warning issued by the Federal Antimonopoly Service (FAS Russia) to “Baxter” CJSC due to elements of violating the antimonopoly law (Clause 5 Part 1 Article 10 of the Federal Law “On Protection of Competition”). The company unreasonably refused to conclude a contract with “Medical Service Company” Ltd. for supping the drug with “Icodextrin” International Non-Proprietary Name (“trade name – “Extranil”).

Earlier FAS warned to “Baxter” CJSC to eliminate the elements of the violation and conclude a contract with “Medical Service Company” Ltd. for supplying “Extranil”.

Considering the warning unlawful and unreasonable, “Baxter” CJSC filed a lawsuit.

Moscow Arbitration Court dismissed the claim, confirming legitimacy of the warning issued by the antimonopoly body.